Rachel Chiaverelli, PhD, has joined GSK as Executive Director, Oncology Early Translational Biomarkers, after nearly four years at Daiichi Sankyo. “This new chapter in my career at GSK is particularly meaningful as I am returning to the place that was pivotal in driving my passion for translational medicine early in my career,” Chiaverelli said. “I am thrilled to bring my experience and passion for oncology translational medicine from early discovery towards patients in need of novel treatment options.”
About Rachel Chiaverelli
Chiaverelli’s return to GSK closes a loop that opened more than a decade ago: she began her career there as a Stress & Repair Biology co-op in the company’s Upper Merion, Pennsylvania, labs, generating cellular models of mitochondrial dysfunction in COPD before going on to build her career in oncology translational medicine and clinical biomarker strategy.
Most recently, Chiaverelli spent nearly four years at Daiichi Sankyo, rising from Director to Senior Director, Translational Sciences Oncology Strategy Lead. Before that, she spent three years at Prelude Therapeutics, advancing from Associate Director to Senior Director, Translational Medicine/Clinical Biomarker Lead. Earlier in her career, she held roles at Champions Oncology in Medical Affairs, Scientific Business Development, and Clinical Operations, and served as a Medical Science Liaison and Medical Science Consultant at The Angiogenesis Foundation. She has also served as an Adjunct Assistant Professor at Temple University since 2021.
Chiaverelli holds a PhD in Biochemical and Molecular Nutrition from Tufts University School of Medicine, where her doctoral research examined the mechanistic role of Sirtuin 1 and β-cryptoxanthin in preventing cigarette smoke-induced inflammatory lung lesions. She also holds a Master of Science in Biotechnology and a Bachelor of Science in Biology from Temple University.
About GSK
GSK is a global biopharma company headquartered in London that discovers, develops, and delivers vaccines and specialty medicines, with active research spanning respiratory and immunology, oncology, HIV, and infectious diseases. The company operates across 70 markets, employs roughly 66,800 people, and has 58 medicines and vaccines in active development. GSK reported group turnover of £32.7 billion in 2025 and has set a goal of positively impacting the health of 2.5 billion people by the end of the decade.
